www.dayvigohcp.com Open in urlscan Pro
208.74.145.245  Public Scan

Form analysis
1 forms found in the DOM

POST /

<form action="/" data-form-name="dayv-hcp-signup" id="dayvigo-signup" method="post" class="signup-form"><input name="__RequestVerificationToken" type="hidden"
    value="FKDZP7TZXGy5nwBcy9Qpgye-tWulJXCrFxX10ILXVlzKZObh47qCszKZm-OwR4wxXLLlVHARr-E2LmaPUB5C1wszvKzgxC0W5a669FM4tAk1"><input id="scController" name="scController" type="hidden" value="DayvigoRegistration"><input id="scAction" name="scAction"
    type="hidden" value="SubmitForm"> <input type="hidden" name="DataSourceItem" value="{65C8713B-66E9-413C-BB49-237105110223}"> <input type="hidden" name="EmailCreative" value="FULL SITE LAUNCH">
  <div role="group" id="__BVID__9" class="form-group"><label for="firstName" id="__BVID__9__BV_label_" class="d-block">FIRST NAME</label>
    <div><input id="firstName" name="FName" placeholder="First Name" aria-label="First Name" class="form-control">
      <div data-required-error="Please enter your first name." data-format-error="Please enter a valid first name." id="firstNameFeedback" class="invalid-feedback">
      </div>
    </div>
  </div>
  <div role="group" id="__BVID__11" class="form-group"><label for="lastName" id="__BVID__11__BV_label_" class="d-block">LAST NAME</label>
    <div><input id="lastName" name="LName" placeholder="Last Name" aria-label="Last Name" class="form-control">
      <div data-required-error="Please enter your last name." data-format-error="Please enter a valid last name." id="lastNameFeedback" class="invalid-feedback">
      </div>
    </div>
  </div>
  <div role="group" id="__BVID__9" class="form-group"><label for="emailAddress" id="__BVID__9__BV_label_" class="d-block">EMAIL ADDRESS</label>
    <div><input id="emailAddress" name="Email" type="text" placeholder="Email Address" aria-label="Email Address" class="form-control">
      <div id="emailAddressFeedback" data-required-error="Please enter a valid email address." data-format-error="Please enter a valid email address." class="invalid-feedback">
      </div>
    </div>
  </div>
  <div role="group" id="__BVID__9" class="form-group"><label for="zipCode" id="__BVID__9__BV_label_" class="d-block">ZIP CODE</label>
    <div><input id="zipCode" name="Zip" maxlength="5" placeholder="ZIP Code" aria-label="ZIP Code" class="form-control">
      <div id="zipCodeFeedback" data-required-error="Please enter a valid ZIP code." data-format-error="Please enter a valid ZIP code." class="invalid-feedback">
      </div>
    </div>
  </div>
  <div role="group" class="form-group" id="__BVID__13"><label for="userType" class="d-block" id="__BVID__13__BV_label_">I AM A</label>
    <div><input id="custType" name="CustType" type="hidden">
      <div id="custom-button-dropdown" class="dropdown btn-group b-dropdown custom-button-dropdown" data-placeholder="--Select one--" aria-label="--Select one--"><!----><button id="custom-button-dropdown__BV_toggle_" aria-haspopup="true"
          aria-expanded="false" type="button" class="btn dropdown-toggle btn-secondary">--Select one--</button>
        <ul role="menu" tabindex="-1" aria-labelledby="custom-button-dropdown__BV_toggle_" class="dropdown-menu">
          <li class="custom-button-dropdown-item"><button role="menuitem" type="button" class="dropdown-item">APN</button></li>
          <li class="custom-button-dropdown-item"><button role="menuitem" type="button" class="dropdown-item">CRNA</button></li>
          <li class="custom-button-dropdown-item"><button role="menuitem" type="button" class="dropdown-item">DO</button></li>
          <li class="custom-button-dropdown-item"><button role="menuitem" type="button" class="dropdown-item">Pharmacist</button></li>
          <li class="custom-button-dropdown-item"><button role="menuitem" type="button" class="dropdown-item">PA</button></li>
          <li class="custom-button-dropdown-item"><button role="menuitem" type="button" class="dropdown-item">MD</button></li>
        </ul>
      </div>
      <div data-required-error="Please select one." id="userTypeFeedback" class="invalid-feedback">
      </div><!----><!----><!---->
    </div>
  </div>
  <div role="group" class="form-group" id="__BVID__21"><label for="isAgreeToTerms" class="d-block" id="__BVID__21__BV_label_">STAY INFORMED</label>
    <div>
      <div class="custom-control custom-checkbox"><input id="isAgreeToTerms" type="checkbox" autocomplete="off" aria-label="STAY INFORMED" class="custom-control-input" value="true"><label for="isAgreeToTerms" class="custom-control-label">
          <p>I certify that I am 18 years of age or older and accept the Terms and Conditions.</p>
        </label></div>
      <div data-required-error="You must agree to the Terms and Conditions." id="isAgreeToTermsFeedback" class="invalid-feedback">
      </div><!----><!----><!---->
    </div>
  </div>
  <div class="form-group"></div>
</form>

Text Content

This site is intended for US Healthcare Professionals

 * This site is intended for
   US Healthcare Professionals
 * Important Safety Information
 * Full Prescribing Information
 * Patient Site
 * REQUEST A REP

REQUEST A REP

×
 * Home
 * Efficacy
 * Safety
 * Getting Started
 * About DAYVIGO
 * Resources

 * Patient Site


THE OPPORTUNITY TO



START HER DAY
WITH A GOOD
NIGHT'S SLEEP1


DAYVIGO (LEMBOREXANT) MAY HELP YOUR PATIENTS GET THE SLEEP THEY NEED TO BEGIN
THEIR MORNINGS.





THE OPPORTUNITY TO



START HIS DAY
WITH A GOOD
NIGHT'S SLEEP1


DAYVIGO (LEMBOREXANT) MAY HELP YOUR PATIENTS GET THE SLEEP THEY NEED TO BEGIN
THEIR MORNINGS.




--------------------------------------------------------------------------------


EFFICACY


View Clinical Data


SAFETY


See the Safety Profile


GETTING STARTED


Getting Started on DAYVIGO

See the Study Results
on Transitioning from a
Commonly Prescribed Insomnia Medication
to DAYVIGO


Explore the
Clinical Study
See How To Get Your Patients
Started With DAYVIGO




×
X


Get to know DAYVIGO and see if the proven starting dose of 5 mg is right for
your patients with insomnia.
Getting Started on DAYVIGO
Patient Assistance and Access
Financial support is available upon
request for eligible patients.
DAYVIGO Resources and Tools
Interested in More Information About DAYVIGO?
Fill out the form below to receive updates.
FIRST NAME

LAST NAME

EMAIL ADDRESS

ZIP CODE

I AM A
--Select one--
 * APN
 * CRNA
 * DO
 * Pharmacist
 * PA
 * MD


STAY INFORMED

I certify that I am 18 years of age or older and accept the Terms and
Conditions.




Terms and Conditions

Please be advised that the personal information you provide will be used to
satisfy your request to receive information from Eisai Inc. Eisai Inc. ("Eisai"
or "we") operates this website and our Privacy Policy will govern the
collection, use, disclosure and retention of the information you provide here.
Please do not submit any personal information unless you have read and agree
with the terms of that Privacy Policy. Consistent with the Privacy Policy, we
and our service providers may use the personal information you provide to
contact you and send you communications, including about products and services
that may interest you. By clicking Submit below, you agree that you have read,
understand, and agree to these conditions.

In the event that you would like to opt out of receiving further communications,
you can request that you be removed from the Eisai contact list at any time by
clicking on the "Unsubscribe" link found at the bottom of all email
communications from Eisai. See our full Privacy Policy.

Submit


YOU’RE SIGNED UP!

Thank you for registering. Be sure to check your inbox to learn more about
DAYVIGO.


SORRY! 

Something went wrong during the processing of your request.
Please come back later and try again.


ALREADY REGISTERED

Our records show that this email address has already been registered.


REFERENCE:

 1. DAYVIGO (lemborexant) [Prescribing Information]. Woodcliff Lake, NJ: Eisai
    Inc.

--------------------------------------------------------------------------------

Expand Collapse


INDICATION

DAYVIGO (lemborexant) is an orexin receptor antagonist indicated for the
treatment of adult patients with insomnia, characterized by difficulties with
sleep onset and/or sleep maintenance.


IMPORTANT SAFETY INFORMATION


CONTRAINDICATIONS

 * DAYVIGO is contraindicated in patients with narcolepsy.


WARNINGS AND PRECAUTIONS

 * Central Nervous System (CNS) Depressant Effects and Daytime Impairment:
   DAYVIGO can impair daytime wakefulness. CNS depressant effects may persist in
   some patients up to several days after discontinuing DAYVIGO. Prescribers
   should advise patients about the potential for next-day somnolence.
   
   Driving ability was impaired in some subjects taking DAYVIGO 10 mg. Risk of
   daytime impairment is increased if DAYVIGO is taken with less than a full
   night of sleep remaining or at a higher than recommended dose. If taken in
   these circumstances, patients should not drive or engage in activities
   requiring mental alertness.
   
   Use with other classes of CNS depressants (e.g., benzodiazepines, opioids,
   tricyclic antidepressants, alcohol) increases the risk of CNS depression,
   which can cause daytime impairment. Dosage adjustments of DAYVIGO and
   concomitant CNS depressants may be necessary when administered together. Use
   of DAYVIGO with other insomnia drugs is not recommended. Patients should be
   advised not to consume alcohol in combination with DAYVIGO.
   
   Because DAYVIGO can cause drowsiness, patients, particularly the elderly, are
   at a higher risk of falls.

 * Sleep Paralysis, Hypnagogic/Hypnopompic Hallucinations, and Cataplexy-Like
   Symptoms:
   Sleep paralysis, an inability to move or speak for up to several minutes
   during sleep-wake transitions, hypnagogic/hypnopompic hallucinations,
   including vivid and disturbing perceptions can occur with DAYVIGO.
   Prescribers should explain these events to patients.
   
   Symptoms similar to mild cataplexy can occur with DAYVIGO and can include
   periods of leg weakness lasting from seconds to a few minutes, can occur
   either at night or during the day, and may not be associated with identified
   triggering event (e.g., laughter or surprise).

 * Complex Sleep Behaviors:
   Complex sleep behaviors, including sleep-walking, sleep-driving, and engaging
   in other activities while not fully awake (e.g., preparing and eating food,
   making phone calls, having sex), have been reported to occur with the use of
   hypnotics such as DAYVIGO. Events can occur in hypnotic-naïve and
   hypnotic-experienced persons. Patients usually do not remember these events.
   Complex sleep behaviors may occur following the first or any subsequent use
   of DAYVIGO, with or without the concomitant use of alcohol and other CNS
   depressants. Discontinue DAYVIGO immediately if a patient experiences a
   complex sleep behavior.

 * Patients with Compromised Respiratory Function:
   The effect of DAYVIGO on respiratory function should be considered for
   patients with compromised respiratory function. DAYVIGO has not been studied
   in patients with moderate to severe obstructive sleep apnea (OSA) or chronic
   obstructive pulmonary disease (COPD).

 * Worsening of Depression/Suicidal Ideation:
   Incidence of suicidal ideation or suicidal behavior, as assessed by
   questionnaire, was higher in patients receiving DAYVIGO than placebo (0.3%
   for DAYVIGO 10 mg, 0.4% for DAYVIGO 5 mg, and 0.2% for placebo). In primarily
   depressed patients treated with hypnotics, worsening of depression and
   suicidal thoughts and actions (including completed suicides) have been
   reported. Suicidal tendencies may be present in such patients and protective
   measures may be required. Intentional overdose is more common in this group
   of patients; therefore, the lowest number of tablets that is feasible should
   be prescribed at any one time. The emergence of any new behavioral sign or
   symptom of concern requires careful and immediate evaluation.

 * Need to Evaluate for Comorbid Diagnoses:
   Treatment of insomnia should be initiated only after careful evaluation of
   the patient. Re-evaluate for comorbid conditions if insomnia persists or
   worsens after 7 to 10 days of treatment. Worsening of insomnia or the
   emergence of new cognitive or behavioral abnormalities may be the result of
   an unrecognized underlying psychiatric or medical disorder and can emerge
   during the course of treatment with sleep-promoting drugs such as DAYVIGO.


ADVERSE REACTIONS

 * The most common adverse reaction (reported in 5% of patients treated with
   DAYVIGO and at least twice the rate of placebo) with DAYVIGO was somnolence
   (10% for DAYVIGO 10 mg, 7% for DAYVIGO 5 mg, 1% for placebo).


DRUG INTERACTIONS

 * CYP3A Inhibitors: The maximum recommended dose of DAYVIGO is 5 mg no more
   than once per night when co-administered with weak CYP3A inhibitors. Avoid
   concomitant use of DAYVIGO with strong or moderate CYP3A inhibitors.

 * CYP3A Inducers: Avoid concomitant use of DAYVIGO with moderate or strong
   CYP3A inducers.


USE IN SPECIFIC POPULATIONS

 * Pregnancy and Lactation: There is a pregnancy exposure registry that monitors
   pregnancy outcomes in women who are exposed to DAYVIGO during pregnancy.
   Healthcare providers are encouraged to register patients in the DAYVIGO
   pregnancy registry by calling 1-888-274-2378. There are no available data on
   DAYVIGO use in pregnant women to evaluate for a drug-associated risk of major
   birth defects, miscarriage, or adverse maternal or fetal outcomes.
   
   There are no data on the presence of lemborexant in human milk, the effects
   on the breastfed infant, or the effects on milk production. Infants exposed
   to DAYVIGO through breastmilk should be monitored for excess sedation.

 * Geriatric Use: Exercise caution when using doses higher than 5 mg in patients
   ≥65 years old.

 * Renal Impairment: Patients with severe renal impairment may experience an
   increased risk of somnolence.

 * Hepatic Impairment: The maximum recommended dose of DAYVIGO is 5 mg in
   patients with moderate hepatic impairment. DAYVIGO is not recommended in
   patients with severe hepatic impairment. Patients with mild hepatic
   impairment may experience an increased risk of somnolence.


DRUG ABUSE AND DEPENDENCE

 * DAYVIGO is a Schedule IV-controlled substance.

 * Because individuals with a history of abuse or addiction to alcohol or other
   drugs may be at increased risk for abuse and addiction to DAYVIGO, follow
   such patients carefully.

For more information about DAYVIGO, see full Prescribing Information.

 * Privacy Policy
 * Legal Notice and Disclaimers
 * Site Map

This site is intended for Healthcare Providers of the United States only.

DAYVIGO® is a registered trademark used by Eisai Inc. under license from Eisai
R&D Management Co., Ltd.

© 2021 Eisai Inc. All rights reserved.

DAYV-US3456 07/2021 us.eisai.com




AN IMPORTANT MESSAGE
FOR OUR PATIENTS AND
HEALTHCARE PROFESSIONALS


×

During the current public health crisis, Eisai Inc. is committed to keeping our
supply chain running safely and supporting those who rely on our medications.

As you explore DAYVIGOHCP.com to learn more about our newest medication, be sure
to take a look at the tools, resources, and financial support we’ve provided to
help you and your patients.

Please see the Resource page for more details.

For Patients For Healthcare
Professionals

Whether you are considering or
currently taking our medications,
please always consult with your
healthcare provider.